Xue Wang,Yuetong Wang,Zhaoyuan Fang,Hua Wang,Jian Zhang,Longfu Zhang,Hsinyi Huang,Zhonglin Jiang,Yujuan Jin,Xiangkun Han,Shenda Hou,Bin Zhou,Feilong Meng,Luonan Chen,Kwok-Kin Wong,Jinfeng Liu,Zhiqi Zhang,Xin Zhang,Haiquan Chen,Yihua Sun,Liang Hu,Hongbin Ji

Abstract:Abstract Somatic mutations of the chromatin remodeling gene ARID2 are observed in ∼7% of human lung adenocarcinomas (LUADs). However, the role of ARID2 in the pathogenesis of LUADs remains largely unknown. Here we find that ARID2 expression is decreased during the malignant progression of both human and mice LUADs. Using two KrasG12D-based genetically engineered murine models, we demonstrate that ARID2 knockout significantly promotes lung cancer malignant progression and shortens overall survival. Consistently, ARID2 knockdown significantly promotes cell proliferation in human and mice lung cancer cells. Through integrative analyses of ChIP-Seq and RNA-Seq data, we find that Hspa1a is up-regulated by Arid2 loss. Knockdown of Hspa1a specifically inhibits malignant progression of Arid2-deficient but not Arid2-wt lung cancers in both cell lines as well as animal models. Treatment with an HSPA1A inhibitor could significantly inhibit the malignant progression of lung cancer with ARID2 deficiency. Together, our findings establish ARID2 as an important tumor suppressor in LUADs with novel mechanistic insights, and further identify HSPA1A as a potential therapeutic target in ARID2-deficient LUADs.

Targeting HSPA1A in ARID2-deficient lung adenocarcinoma